Cargando…

WS21.03 Low-cost chain termination DNA sequencing PCR reaction to diagnose CFTR gene mutations

Detalles Bibliográficos
Autores principales:	Ghani, M.U., Sabar, M.F., Awan, F.I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Cystic Fibrosis Society. 2022
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184788/ http://dx.doi.org/10.1016/S1569-1993(22)00275-2

Ejemplares similares

WS21.01 AQP5 and CFTR, two genes associated with pseudo-aquagenic palmoplantar keratoderma?
por: Girodon, E., et al.
Publicado: (2022)

WS05.04 SARS-CoV-2 infection is reduced in both immortalised and primary CFTR-modulated human bronchial epithelial cells
por: Lotti, V., et al.
Publicado: (2022)

WS20.06 Co-infection with Nocardia farcinia and SARS-CoV-2 causing the death of an adolescent with cystic fibrosis
por: Chapman, J., et al.
Publicado: (2022)

WS20.02 Input supporting a young person with increased cough suppression in the context of COVID-19
por: Shayle, A., et al.
Publicado: (2022)

S185: TARGETING DNA2 OVERCOMES METABOLIC REPROGRAMMING IN 1Q21 MULTIPLE MYELOMA
por: Thongon, Natthakan, et al.
Publicado: (2023)

S234: CLINICAL-GRADE MBIL21/4-1BBL EXPANDED NK CELLS EXHIBIT STRONGER COMPETENCE COMPARED WITH PRIMARY NK CELLS AGAINST HCMV INFECTION
por: Shang, Q.-N., et al.
Publicado: (2022)

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL
por: Jabbour, Elias, et al.
Publicado: (2023)

Oral Session 03: CNS Risk
por: Narici, Livio, et al.
Publicado: (2014)

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
por: Costa, Luciano, et al.
Publicado: (2023)

S114: OUTCOME OF OLDER PATIENTS (>55 YRS) WITH NEWLY DIAGNOSED PH/BCR:ABL POSITIVE ALL PROSPECTIVELY TREATED ACCORDING TO PEDIATRIC-BASED, AGE-ADAPTED GMALL PROTOCOLS
por: Lang, Fabian, et al.
Publicado: (2023)

S133: AN ENTIRELY ORAL REGIMEN OF ORAL-ATO, ATRA AND ASCORBIC ACID IN RISK-ADAPTED TREATMENT OF NEWLY-DIAGNOSED APL RESULTED IN EXCELLENT CLINICAL/MOLECULAR RESPONSES WITH DURABLE REMISSION
por: Gill, Harry, et al.
Publicado: (2023)

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
por: Litzow, Mark, et al.
Publicado: (2023)

S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703
por: Wieduwilt, Matthew, et al.
Publicado: (2023)

S215: KEYNOTE-667: OPEN-LABEL, PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT-LINE CHEMOTHERAPY
por: Vinti, Luciana, et al.
Publicado: (2023)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
por: Montesinos, Pau, et al.
Publicado: (2023)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
por: Miguel Bergua Burgues, Juan, et al.
Publicado: (2023)

WS07.06 CFTR impacts SARS-CoV-2 infection in cystic fibrosis
por: Bragonzi, A., et al.
Publicado: (2023)

S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
por: Duarte, Rafael F, et al.
Publicado: (2023)

S266: DIFFERENT MOLECULAR VASO-OCCLUSIVE TRIGGERS STIMULATE DISTINCT VASO-OCCLUSIVE PROFILES: IN VIVO RESULTS FROM MICE WITH SICKLE CELL ANEMIA
por: Gushiken, Lucas F. S., et al.
Publicado: (2023)

Infections inhabituelles
Publicado: (2011)

Grippe A (H1N1) en réanimation
Publicado: (2010)

ECMO veinoveineuse
Publicado: (2013)

AB03. Intermittent androgen suppression: current status
por: Goldenberg, Larry
Publicado: (2014)

WS1.4: BIOSTIMULATION OF BACTERIA FOR STREAMLINED IDENTIFICATION OF NEW ANTIMICROBIAL COMPOUNDS
por: Mirzaee, Hooman, et al.
Publicado: (2022)

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
por: Hernández-Sánchez, A., et al.
Publicado: (2022)

Rhinitis, sinusitis and ocular disease – 2103. Comparative allergen profile in Krishna – Godavari region
por: Gonuguntla, Hari Kishan, et al.
Publicado: (2013)

PB2103: PROGNOSTIC PROFILING OF PATIENTS WITH MULTIPLE MYELOMA: THE GAME OF SCORES-DOES IT MATTER?
por: Sretenovic, Aleksandra, et al.
Publicado: (2023)

S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A
por: Perner, Florian, et al.
Publicado: (2023)

S131: CLINICAL IMPLICATIONS OF SECONDARY-AML TYPE MUTATIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA
por: Sun, K., et al.
Publicado: (2022)

S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT
por: Ahmed, Nausheen, et al.
Publicado: (2023)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023)

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
por: Rücker, Frank G, et al.
Publicado: (2023)

OA03.02. Acupuncture for back pain: predicting attendance at appointments
por: Bishop, F, et al.
Publicado: (2012)

P402 Comparison of PCR-RFLP with 21-plex PCR and rDNA: sequencing for identification of clinical yeast isolates
por: Khodavaisy, Sadegh, et al.
Publicado: (2022)

2103. Comparison of Antibiograms Across Solid Organ Transplant Services Within a Medical Center
por: Kim, Annie, et al.
Publicado: (2022)

OA09.03. Stress reduction using massage in cardiac surgery patients
por: Braun, L, et al.
Publicado: (2012)

S116: CELLULAR AND MOLECULAR MECHANISMS OF EVI1-EXPRESSING MLL-REARRANGED ACUTE MYELOID LEUKEMIA
por: Châtel-Soulet, Hugues-Etienne, et al.
Publicado: (2022)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
por: Daver, N. G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_70i8ph442j3n75ibe81p4h9g8k